Medullary thyroid carcinoma and hormones

Annales de Medecine Interne

Volumn 154, Issue 2, 2003, Pages 109-116

  Cohen, Régis ^a   Quidville, Virginie ^b   Bihan, Hélène ^a  

^a AVICENNE HOSPITAL   (France)

^b CENTRE VIGGO PETERSEN   (France)

Author keywords

Calcitonine; Hormones; Medullary thyroid carcinoma; Nonsteroidal anti inflammatory drugs; Somatostatin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CALCITONIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PENTAGASTRIN; PIROXICAM; PROSTAGLANDIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SULINDAC; DRUG DERIVATIVE; HORMONE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TUMOR MARKER;

ABDOMINAL PAIN; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; COLON POLYP; CONFERENCE PAPER; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FLUSHING; HORMONE BLOOD LEVEL; HUMAN; HYPOTENSION; IN VITRO STUDY; MUSCLE WEAKNESS; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PROSTAGLANDIN SYNTHESIS; RECTUM POLYP; SKIN MANIFESTATION; STOMACH HEMORRHAGE; STOMACH ULCER; TACHYCARDIA; THORAX PAIN; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; VISUAL IMPAIRMENT; VOMITING; BLOOD; MEDULLARY CARCINOMA; METABOLISM; REVIEW; THYROID TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCITONIN; CARCINOMA, MEDULLARY; HORMONES; HUMANS; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; SOMATOSTATIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0042320978     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (77)

1. MILHAUD G, TUBIANA M, PARMENTIER C, COUTRIS G. [Epithelioma of the thyroid secreting thyrocalcitonin]. C R Acad Sci Hebd Seances Acad Sci D 1968; 266: 608-10.
2. CALMETTES C. [Medullary cancer of the thyroid]. Bull Cancer 1990; 77: 1063-72.
3. MODIGLIANI E, COHEN R, CAMPOS JM, CONTE-DEVOLX B, MAES B, BONEU A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group (Groupe d'Étude des Tumeurs à Calcitonine). Clin Endocrinol (Oxf) 1998; 48: 265-73.
4. MULLIGAN LM, KWOK JB, HEALEY CS, ELSDON MJ, ENG C, GARDNER E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
5. HESHMATI HM, HOFBAUER LC. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Eur J Endocrinol 1997; 137: 572-8.
6. HAZARD JB, HAWK WA, CRILE G. Medullary (solid) carcinoma of the thyroid. A clinicopathological entity. J Clin Endocrinol Metab 1959; 19: 152-61.
7. SIPPLE JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961; 31: 163-5.
8. GORLIN RJ, SEDANO HO, VICKERS RA, CERVENKA J. Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid: a syndrome. Cancer 1968; 22: 293-9.
9. MILHAUD G, COUTRIS G, TUBIANA M. [Thyroid medullary cancer: does the hyperthyrocalcitonin syndrome exist?]. Probl Actuels Endocrinol Nutr 1969; 13: 111-33.
10. COOPER CW, SCHWESINGER WH, MAHGOUB AM, ONTJES DA. Thyrocalcitonin: stimulation of secretion by pentagastrin. Science 1971; 172: 1238-40.
11. AMARA SG, JONAS V, ROSENFELD MG, ONG ES, EVANS RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982; 298: 240-4.
12. CALMETTES C, CAILLOU B, MILHAUD G. [Plurality of calcitonin-producing thyroid cancers]. Presse Med 1983; 12: 1167-70.
13. MATHEW CG, CHIN KS, EASTON DF, THORPE K, CARTER C, LIOU GI, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987; 328: 527-8.
14. SIMPSON NE, KIDD KK, GOODFELLOW PJ, MCDERMID H, MYERS S, KIDD JR, et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987; 328: 528-30.
15. LIPS CJ, LANDSVATER RM, HOPPENER JW, GEERDINK RA, BLIJHAM G, VAN VEEN JM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331: 828-35.
16. SCHOTT M, SEISSLER J, LETTMANN M, FOUXON V, SCHERBAUM WA, FELDKAMP J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001; 86: 4965-9.
17. GULIANA JM, MODIGLIANI E. [Tumor markers of medullary cancer of the thyroid body. Basic and endocrine aspects]. Ann Endocrinol (Paris) 1988; 49: 34-50.
18. LE MOULLEC JM, JULLIENNE A, CHENAIS J, LASMOLES F, GULIANA JM, MILHAUD G, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984; 167: 93-7.
19. BECKER KL, MÜLLER B, NYLEN ES, COHEN RS, OL, WHITE JC, SNIDER RHJ. Calcitonin gene family of peptides. Third edition. Philadelphia: Lippincott/Williams and Wilkins, 2001.
20. REDDING AH, LEVINE SN, FOWLER MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000; 10: 919-22.
21. COOPER CW. Recent advances with thyrocalcitonin. Ann Clin Lab Sci 1976; 6: 119-29.
22. BARBOT N, CALMETTES C, SCHUFFENECKER I, SAINT-ANDRE JP, FRANC B, ROHMER V, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 114-20.
23. BARBOT N, SCHUFFENECKER I, CALMETTES C, MODIGLIANI E, LENOIR G, BIGORGNE JC. Conditions actuelles du dépistage du carcinome médullaire de la thyroïde. Rev Fr Endocrinol Clin 1993; 34: 539-48.
24. GUILLOTEAU D, PERDRISOT R, CALMETTES C, BAULIEU JL, LECOMTE P, KAPHAN G, et al. Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab 1990; 71: 1064-7.
25. SCHEUBA C, KASERER K, KOTZMANN H, BIEGLMAYER C, NIEDERLE B, VIERHAPPER H. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin. Thyroid 2000; 10: 413-6.
26. HAHM JR, LEE MS, MIN YK, LEE MK, KIM KW, NAM SJ, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001; 11: 73-80.
27. PACINI F, FONTANELLI M, FUGAZZOLA L, ELISEI R, ROMEI C, DI COSCIO G, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 826-9.
28. RIEU M, LAME MC, RICHARD A, LISSAK B, SAMBORT B, VUONG-NGOC P, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) 1995; 42: 453-60.
29. SHONG YK, CHO BY, HY P, BY C. Clinical significance of routine measurement of serum calcitonin in Korean patients with thyroid nodules as a screening test of sporadic thyroid medullary carcinoma. J Kor Soc Endocrinol 1996; 3: 11-7.
30. HENRY JF, DENIZOT A, PUCCINI M, NICCOLI P, CONTE-DEVOLX B, DE MICCO C. [Early diagnosis of sporadic medullary cancers of the thyroid: value of systematic assay of calcitonin]. Presse Med 1996; 25: 1583-8.
31. NICCOLI P, WION-BARBOT N, CARON P, HENRY JF, DE MICCO C, SAINT-ANDRE JP, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82: 338-41.
32. VIERHAPPER H, RABER W, BIEGLMAYER C, KASERER K, WEINHAUSL A, NIEDERLE B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589-93.
33. KASERER K, SCHEUBA C, NEUHOLD N, WEINHAUSEL A, VIERHAPPER H, HAAS OA, et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol 1998; 22: 722-8.
34. OZGEN AG, HAMULU F, BAYRAKTAR F, YILMAZ C, TUZUN M, YETKIN E, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999; 9: 579-82.
35. COHEN R, CAMPOS JM, SALAUN C, HESHMATI HM, KRAIMPS JL, PROYE C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs à Calcitonine (GETC). J Clin Endocrinol Metab 2000; 85: 919-22.
36. VITALE G, CARAGLIA M, CICCARELLI A, LUPOLI G, ABBRUZZESE A, TAGLIAFERRI P. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001; 91: 1797-808.
37. SNIDER RHJ, NYLEN ES, BECKER KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Invest Med 1997; 45: 552-60.
38. MOTTE P, VAUZELLE P, GARDET P, GHILLANI P, CAILLOU B, PARMENTIER C, et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin Chim Acta 1988; 174: 35-54.
39. CONLON JM, GRIMELIUS L, THIM L. Structural characterization of a high-molecular-mass form of calcitonin [procalcitonin-(60-116)-peptide] and its corresponding N-terminal flanking peptide [procalcitonin-(1-57)-peptide] in a human medullary thyroid carcinoma. Biochem J 1988; 256: 245-50.
40. SNIDER RHJ, SILVA OL, MOORE CF, BECKER KL. Immunochemical heterogeneity of calcitonin in man: effect on radioimmunoassay. Clin Chim Acta 1977; 76: 1-14.
41. WHANG KT, STEINWALD PM, WHITE JC, NYLÉN ES, SNIDER RHJ, SIMON GL, et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998; 83: 3296-301.
42. MÜLLER B, BECKER KL, SCHÄCHINGER H, RICKENBACHER PR, HUBER PR, ZIMMERLI W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977-83.
43. BIHAN H, BECKER KL, SNIDER RH, NYLEN ES, VITTAZ L, LAURET C, et al. Medullary thyroid carcinoma: clinical utility of serum calcitonin precursors as a marker. The Endocrine Society's 84th Annual Meeting, San Francisco, 2002: P1-158.
44. SAAD MF, ORDONEZ NG, GUIDO JJ, SAMAAN NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1984; 59: 850-6.
45. FRANC B, ROSENBERG-BOURGIN M, CAILLOU B, DUTRIEUX-BERGER N, FLOQUET J, HOUCKE-LECOMTE M, et al. Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis). Hum Pathol 1998; 29: 1078-84.
46. NELKIN BD, CHEN KY, DE BUSTROS A, ROOS BA, BAYLIN SB. Changes in calcitonin gene RNA processing during growth of a human medullary thyroid carcinoma cell line. Cancer Res 1989; 49(24 Pt 1): 6949-52.
47. ISHII J KS, ITABASHI A, TAKAHAMA M, KAWAZU S. Salmon calcitonin induces pituitary tumor in rats. Endocrinol Jpn 1991; 38: 705-9.
48. FRENDO JL, DELAGE-MOURROUX R, COHEN R, PICHAUD F, PIDOUX E, GULIANA JM, et al. Calcitonin receptor mRNA is expressed in human medullary thyroid carcinoma. Thyroid 1998; 8: 141-7.
49. REUBI JC, CHAYVIALLE JA, FRANC B, COHEN R, CALMETTES C, MODIGLIANI E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-73.
50. BAUDIN E, LUMBROSO J, SCHLUMBERGER M, LECLERE J, GIAMMARILE F, GARDET P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-6.
51. GEELHOED GW, BASS BL, MERTZ SL, BECKER KL. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia. Surgery 1986; 100: 962-70.
52. SCHREZENMEIR J, PLEWE G, STURMER W, KAHALY G, OPPERMAN D, KRAUSE U, et al. Treatment of APUDomas with the log-acting somatostatin analogue SMS 201-995. Scand J Gastroenterol 1986; 21: 223-7.
53. AHLMAN H, TISELL LE. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol 1987; 22: 938-42.
54. JERKINS TW, SACKS HS, O'DORISIO TM, TUTTLE S, SOLOMON SS. Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion: a new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 1987; 64: 1313-9.
55. KEELING CA, BASSO LV. Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin. Clin Nucl Med 1988; 13: 260-3.
56. GULIANA JM, GUILLAUSSEAU PJ, CARON J, SIAME-MOUROT C, CALMETTES C, MODIGLIANI E. Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm Metab Res 1989; 21: 584-6.
57. LIBROIA A, VERGA U, DI SACCO G, PIOLINI M, MURATORI F. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma. Henry Ford Hosp Med J 1989; 37: 151-3.
58. MAHLER C, VERHELST J, DE LONGUEVILLE M, HARRIS A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 1990; 33: 261-9.
59. MODIGLIANI E, COHEN R, JOANNIDIS S, SIAME-MOUROT C, GULIANA JM, CHARPENTIER G, et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1992; 36: 183-6.
60. SMID WM, DULLAART RP. Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth J Med 1992; 40: 240-3.
61. KVOLS LK, REUBI JC, HORISBERGER U, MOERTEL CG, RUBIN J, CHARBONEAU JW. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 1992; 65: 505-18 (discussion 531-6).
62. ZLOCK DW, GREENSPAN FS, CLARK OH, HIGGINS CB. Octreotide therapy in advanced thyroid cancer. Thyroid 1994; 4: 427-31.
63. FRANK-RAUE K, RAUE F, ZIEGLER R. [Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide]. Med Klin 1995; 90: 63-6.
64. DIEZ J, IGLESIAS P, SALVADOR J. Somatostatin analogs octreotide and lanttreotide in the therapy of medullary thyroid carcinoma. The Endocrine Society's 84th Annual Meeting. San Francisco, 2002.
65. LUPOLI G, CASCONE E, ARLOTTA F, VITALE G, CELENTANO L, SALVATORE M, et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1996; 78: 1114-8.
66. VITALE G, TAGLIAFERRI P, CARAGLIA M, RAMPONE E, CICCARELLI A, BIANCO AR, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 983-8.
67. KWEKKEBOOM DJ, REUBI JC, LAMBERTS SW, BRUINING HA, MULDER AH, OEI HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413-7.
68. HERSCHMAN HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994; 13: 241-56.
69. WILLIAMS ED, KARIM SM, SANDLER M. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated idarrhoea. Lancet 1968; 6: 22-3.
70. JAFFRE BM, PARKER CW, PHILPOTT GW. Immunochemical measurement of prostaglandin-like activity from normal and neoplastic cultured tissue. Surg Forum 1971; 22: 90-2.
71. WILLIAMS CS, MANN M, DUBOIS RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16.
72. TURINI ME, DUBOIS RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53: 35-57.
73. FOSSLIEN E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
74. GIARDIELLO FM, HAMILTON SR, KRUSH AJ, PIANTADOSI S, HYLIND LM, CELANO P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6.
75. STEINBACH G, LYNCH PM, PHILLIPS RKS, WALLACE MH, HAWK E, GORDON GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
76. FRENKIAN M, SEGOND N, PIDOUX E, COHEN R, JULLIENNE A. Indometacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins Other Lipid Mediat 2000; 65: 11-20.
77. RAO CV, WANG CX, SIMI B, LUBET R, KELLOFF G, STEELE V, et al. Enhancement of experimental colon cancer by genistein. Cancer Res 1997; 57: 3717-22.